

Sangamo Therapeutics Logo

Sangamo BioSciences Announces Third Quarter 2016 Conference Call and Webcast

October 19, 2016

RICHMOND, Calif., Oct. 19, 2016 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, announced today that the company will release its third quarter 2016 financial results after the market closes on Wednesday, October 26, 2016. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the quarter's financial results and discuss other business matters.



The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 96289087. Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors Relations section under [Events and Presentations](#). For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on October 26, 2016 to 11:59 p.m. ET on November 2, 2016. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 96289087.

About Sangamo

Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures[®] for monogenic and infectious diseases by deploying its novel zinc finger DNA-binding protein technology, in therapeutic genome editing and gene regulation, and AAV-based gene therapy platforms. The Company's proprietary ZFN-mediated *in vivo* genome editing approach is focused on monogenic diseases, including hemophilia and lysosomal storage disorders. Based on its *in vivo* genome editing approach, Sangamo is initiating a Phase 1/2 clinical trial for hemophilia B, the first *in vivo* genome editing application cleared by the FDA. In addition, Sangamo has a Phase 2 clinical program to evaluate the safety and efficacy of novel ZFP Therapeutics[®] for the treatment of HIV/AIDS (SB-728). The Company has also formed a strategic collaboration with Biogen Inc. for hemoglobinopathies, such as sickle cell disease and beta-thalassemia, and with Shire International GmbH to develop therapeutics for Huntington's disease. It has established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company's website at www.sangamo.com.

ZFP Therapeutic[®] is a registered trademark of Sangamo BioSciences, Inc.

Logo - <https://photos.prnewswire.com/prnh/20130102/SE35903I.IMG>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/sangamo-biosciences-announces-third-quarter-2016-conference-call-and-webcast-300347671.html>

SOURCE Sangamo BioSciences, Inc.

Released October 19, 2016